Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 15/20 | 0.48 |
| ▸ | GUCY1A2 | P33402 | 15/20 | 0.48 |
| ▸ | GUCY1A1 | Q02108 | 15/20 | 0.48 |
| ▸ | GUCY1B1 | Q02153 | 15/20 | 0.48 |
| ▸ | BUB1 | O43683 | 4/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16806829 | 0.87 | GUCY1B2 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL16906888 | 0.85 | GUCY1B2 (0.47) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL16806876 | 0.84 | GUCY1B2 (0.49) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL16806885 | 0.83 | GUCY1B2 (0.50) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL16806976 | 0.83 | GUCY1B2 (0.47) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL23639438 | 0.82 | GUCY1B2 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL16081904 | 0.82 | GUCY1B2 (0.72) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16807024 | 0.80 | GUCY1B2 (0.49) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL16806614 | 0.80 | GUCY1B2 (0.49) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 | |
| SCHEMBL16807324 | 0.79 | GUCY1B2 (0.49) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214364-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2021-07-15 | — | — | US | disclosed |
| EP-3092231-B1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20160324856-A1 | USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | CYCLERION THERAPEUTICS, INC. | 2016-11-10 | — | — | US | disclosed |
| US-20160324856-A1 | USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | CYCLERION THERAPEUTICS, INC. | 2016-11-10 | — | — | US | disclosed |
| US-20160311826-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160311826-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| WO-2015106268-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015089182-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324856-A1 | USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | SMN1; SMN2, PRKG1, GUCY1A2 | GUCY1B2 8/4885GUCY1A2 3/4885GUCY1A1 6/4885 |
| US-20160311826-A1 | SGC STIMULATORS | GUCY1A1, GUCY1B1, GUCY1A2 | GUCY1B2 4/4885GUCY1A2 3/4885GUCY1A1 1/4885 |
| US-20210214364-A1 | sGC STIMULATORS | GUCY1B1, GUCY1A1, GUCY1B2 | GUCY1B2 3/4885GUCY1A2 4/4885GUCY1A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.